Envenenamiento de la sangre

2'-Fucosyllactose (2'-FL) is the most abundant human milk oligosaccharide (HMO). Research demonstrates it acts as a prebiotic supporting Bifidobacterium and Akkermansia muciniphila growth, enhancing intestinal barrier function, modulating immune responses, and ameliorating food allergy in animal models—all directly relevant to food sensitivity.

Akkermansia muciniphila is a mucin-degrading gut bacterium with emerging evidence for improving intestinal barrier function by enhancing tight junction protein expression and mucus layer thickness—mechanisms directly relevant to food sensitivity. In vitro and animal studies, and increasingly clinical evidence, show A. muciniphila fortifies the gut barrier against food antigen translocation.

Alpha-galactosidase hydrolyzes galacto-oligosaccharides (GOS) found in beans, legumes, and certain vegetables that humans cannot digest endogenously, thereby preventing fermentation-related gas, bloating, and abdominal discomfort—symptoms that constitute a food sensitivity to these foods. A double-blind crossover RCT (Ganiats et al., J Fam Pract 1994) and a subsequent RCT confirmed significant reductions in flatulence and breath hydrogen after bean-rich meals. A pediatric RCT (PMC3849317) also found significant improvement in gas-related symptoms.

Amylase breaks down complex carbohydrates and starches; amylase supplementation is used in digestive enzyme blends to reduce food sensitivity symptoms related to carbohydrate maldigestion, including bloating and gas. Clinical and in vitro research supports its role in enhancing carbohydrate digestion in sensitive individuals.

Aspergillopepsin (ASP), an aspartyl protease from Aspergillus niger, is used in digestive enzyme supplements targeting gluten sensitivity. When combined with DPP-IV, the pair can degrade gluten peptides including immunogenic fragments; a double-blind RCT in NCGS individuals using an ASP-containing multi-enzyme formula showed clinical benefit.

AN-PEP (A. niger prolyl endoprotease) has been studied in randomized controlled trials specifically targeting non-celiac gluten sensitivity, demonstrating significant reduction of gluten reaching the duodenum. A separate RCT using an Aspergillus oryzae-derived enzyme mixture showed significantly improved symptom scores in patients with non-celiac gluten sensitivity (NCGS). These studies collectively support a clinically relevant role for Aspergillus-derived enzymes in managing food sensitivity to gluten-containing foods.

B. coagulans metabolizes a broad range of dietary sugars (lactose, fructose, sorbitol, maltose, sucrose, inulin, mannan) rapidly within the small intestine, preventing their fermentation in the colon and the resultant GI symptoms associated with carbohydrate sensitivity and malabsorption. This mechanism is documented in both patent literature and mechanistic reviews.

Bifidobacterium species are well-documented probiotics with clinical evidence supporting improvement of gut barrier function and reduction of intestinal permeability, which are central mechanisms in food sensitivity. A systematic review of 52 RCTs (2025) confirms Bifidobacterium and Lactobacillus as the leading genera in probiotic interventions with positive gut barrier effects.

Bifidobacterium breve has demonstrated clinical evidence for improving gut barrier function, with an RCT (PMC8834517) showing significant improvement in intestinal permeability when administered as part of a multi-strain probiotic in elderly subjects. It is also studied for safety in human exercise-induced intestinal permeability models.

B. animalis subsp. lactis Bi-07 has been shown in two clinical trials and an EFSA review to support lactose digestion in individuals with lactose maldigestion, via β-galactosidase (lactase) activity. The strain was found to be superior to placebo and in one trial non-inferior to lactase supplementation for lactose digestion.

Bifidobacterium longum has been used in clinical RCTs demonstrating improvement in intestinal permeability and gut barrier function relevant to food sensitivity. An RCT in elderly subjects using B. longum in a multi-strain formula significantly improved permeability biomarkers, and perioperative supplementation with B. longum reduced post-surgical gut barrier disruption.

Bromelain, a cysteine protease from pineapple stem, aids protein digestion and has been studied for its role in reducing gut permeability-related food sensitivity symptoms. Animal and in vitro research (PMC9696696) show bromelain modulates gut microbiota, increasing beneficial Akkermansia muciniphila and enhancing protein digestive capacity. Bromelain is used clinically in digestive enzyme blends to support breakdown of food proteins in sensitive individuals.

Brown rice protein is broadly recognized as hypoallergenic, being free from all eight major food allergens (milk, egg, peanut, tree nuts, wheat, soy, fish, shellfish). Rice is classified as hypoallergenic — meaning low allergenic potential — and this property makes it a medically-endorsed alternative protein source for individuals with dairy, soy, gluten, or multiple food protein intolerances. This characteristic is well-documented in nutritional science and clinical nutrition literature.

Bovine colostrum contains high concentrations of immunoglobulins (especially IgG), lactoferrin, and growth factors that support gut barrier repair and immune modulation. It has been studied for improving intestinal permeability and is used clinically to support individuals with food sensitivity and leaky gut, with clinical evidence for its gut barrier-strengthening effects.

Diamine oxidase (DAO) is the primary intestinal enzyme responsible for degrading dietary histamine, and its deficiency is the main mechanism behind histamine intolerance—a form of food sensitivity. Randomized clinical trials show DAO supplementation taken before meals significantly reduces gastrointestinal discomfort, headache, and other histamine-mediated symptoms. A crossover RCT also demonstrated that DAO supplementation reduces migraine incidence in patients with DAO deficiency.

Dipeptidyl peptidase IV (DPP-IV) is a serine peptidase used as an enzyme supplement to help degrade gluten peptides and casein peptides in food sensitivity management, particularly for non-celiac gluten sensitivity. Studies show that in combination with other proteases, DPP-IV-containing formulas benefit NCGS patients, though DPP-IV alone has limited efficacy due to its inability to cleave internal peptide bonds.

Exopeptidase supplementation has been investigated as a means to degrade immunogenic peptides—particularly gluten-derived fragments—that trigger food sensitivity reactions. Clinical research demonstrates that exopeptidase combinations can significantly increase the degradation of the proline-rich 33-mer gluten peptide in humans. This evidence is most directly relevant to non-celiac gluten/wheat sensitivity, where undigested peptides drive adverse responses.

Fructooligosaccharides (FOS) are non-digestible prebiotic fibers that selectively stimulate beneficial gut bacteria (Bifidobacterium, Lactobacillus), modulate gut immunity, and are studied in the context of reducing food allergy risk and improving GI function in food sensitivity. A systematic review confirmed FOS selectively promotes beneficial gut microbiota and reduces pro-inflammatory cytokines.

Fungal proteases derived from Aspergillus species have demonstrated the ability to degrade gluten peptides in the stomach before they reach the small intestine, reducing post-prandial gluten concentrations and symptom scores in gluten-sensitive individuals. A prolyl endopeptidase from Aspergillus niger (AN-PEP) and multi-fungal protease blends are the best-studied preparations. Evidence comes from multiple randomized crossover trials.

Alpha-galactosidase directly addresses a well-documented universal food sensitivity to galacto-oligosaccharides (GOS). Because humans lack endogenous alpha-galactosidase in the gut, GOS is universally malabsorbed; in sensitive individuals this triggers bloating, gas, and discomfort. A 2018 RCT by Tuck et al. in the American Journal of Gastroenterology showed that full-dose alpha-galactosidase significantly reduced overall symptoms and bloating in GOS-sensitive IBS patients.

Reduced or absent MGAM activity leads to incomplete starch digestion, generating symptoms (bloating, gas, diarrhea, cramping) that closely mimic carbohydrate food sensitivities. Genetic studies have linked MGAM variants to symptomatic carbohydrate maldigestion, and enzyme supplementation may reduce these reactions.

Glutenases are specialized enzymes (including prolyl endopeptidases and aspergillopepsins) that degrade immunogenic gluten peptides. They are used specifically for gluten sensitivity, particularly non-celiac gluten sensitivity (NCGS). A double-blind RCT in NCGS individuals and multiple clinical studies show benefit in reducing gluten-mediated symptoms, while a published RCT (Clin Nutr 2022) showed a proline-specific endopeptidase allowed gluten reintroduction in NCGS patients.

Hemicellulase addresses a biochemical form of food sensitivity: the inability to digest hemicellulosic plant fibers found in legumes, grains, and vegetables. Humans lack endogenous enzymes to break down these fibers, leading to gas, bloating, and discomfort in sensitive individuals. Enzyme blends containing hemicellulase and xylanase (a hemicellulase subtype) are used clinically in food intolerance formulations to improve tolerance of fiber-rich foods.

Inulin is a long-chain fructan prebiotic fiber that promotes Bifidobacterium and Lactobacillus growth, supports gut barrier function, and is included in clinical dietary strategies for managing GI food sensitivities. A systematic review and meta-analysis confirmed that inulin supplementation produces consistent prebiotic effects and is studied for intestinal permeability improvement.

L-glutamine is a conditionally essential amino acid that serves as the primary fuel for intestinal enterocytes and has been studied clinically for its role in maintaining and restoring gut barrier integrity—the central mechanism in leaky gut-related food sensitivity. A systematic review and meta-analysis of RCTs (PMC11471693) found high-dose glutamine (>30 g/day) significantly reduced intestinal permeability.

Lactase is the intestinal enzyme that hydrolyzes lactose; its deficiency is the direct cause of lactose intolerance, a highly prevalent food sensitivity. Multiple RCTs, including a crossover placebo-controlled trial (PMC7812489), show oral lactase supplementation significantly reduces GI symptoms and breath hydrogen excretion in lactose-intolerant individuals. It is recognized by Harvard Medical School, the NIH, and government health bodies as an established dietary management strategy.

Lactobacillus species are widely studied probiotics shown in clinical and systematic review evidence to modulate intestinal permeability and immune responses relevant to food sensitivity. Systematic reviews including 52 RCTs (Sci Direct 2025) confirm Lactobacillus species as the most common probiotics in studies yielding positive gut barrier improvements.

Lactobacillus acidophilus is a well-studied probiotic strain shown in clinical studies to improve intestinal barrier function and reduce gut permeability markers relevant to food sensitivity. It is frequently included in multi-strain probiotic formulas evaluated in RCTs for gut barrier support and reduction of food antigen translocation.

Lactobacillus plantarum has demonstrated robust effects on intestinal barrier function in RCTs. A perioperative study showed L. plantarum in combination improved small intestinal mucosal barrier integrity and reduced serum zonulin, and it is a leading strain in gut permeability research directly relevant to food sensitivity mechanisms.

Lactobacillus reuteri has been studied in pre- and postnatal supplementation trials showing decreased allergen responsiveness in infancy, making it relevant to food sensitivity prevention. It modulates gut immune responses through multiple mechanisms including regulatory T-cell induction.

Lactobacillus rhamnosus (notably strain GG) is among the most researched probiotic strains for gut barrier support and has been studied in clinical trials for food allergy and intolerance. Pre- and postnatal supplementation with L. rhamnosus GG has shown effects on reducing food allergy risk and modulating gut permeability in clinical studies.

Lipase catalyzes hydrolysis of dietary fats and is a standard component of digestive enzyme therapy for fat maldigestion-related food sensitivity, particularly in conditions of pancreatic insufficiency. Clinical evidence (PMC4923703) and recognized medical guidelines support lipase supplementation for improving fat digestion and reducing GI symptoms in enzyme-deficient and intolerant individuals.

Molybdenum is required for sulfite oxidase, the enzyme that converts food-derived sulfites into non-toxic sulfates. Insufficient sulfite oxidase activity — from rare genetic deficiency or theoretically from low molybdenum — can lead to sulfite accumulation and food sensitivity reactions such as headaches, asthma-like symptoms, and digestive upset. This link is mechanistically well-established, though direct RCT evidence for supplementation in food-sensitive individuals is limited.

Papain, a cysteine protease from papaya latex, supports digestion of dietary proteins and has been shown in animal and in vitro research to modulate gut microbiota beneficially and support mucosal integrity relevant to food sensitivity. It is commonly included in multi-enzyme digestive formulas used for protein food sensitivities.

Prolyl endopeptidase (PEP) is a serine protease that cleaves proline-rich gluten peptides resistant to human digestive enzymes, directly addressing the mechanism of gluten sensitivity. A randomized trial (Clin Nutr 2022) showed a proline-specific PEP allowed gluten reintroduction in NCGS patients; additional studies confirm its ability to significantly reduce gluten immunogenic peptides in vivo.

Specialized peptidases, particularly prolyl endopeptidases (PEP) and DPP-IV, have been studied for their ability to degrade immunogenic gluten peptides that trigger reactions in gluten-sensitive individuals. A randomized, placebo-controlled crossover trial found that Aspergillus niger-derived PEP (AN-PEP) significantly degraded gluten in the stomach of self-reported gluten-sensitive subjects. Evidence is strongest for non-celiac gluten sensitivity rather than celiac disease.

Quercetin is a flavonoid that stabilizes mast cells, reduces histamine release, inhibits tryptase, and supports gut barrier integrity. These properties make it directly relevant to food sensitivity involving histamine intolerance, IgG-mediated reactions, and increased intestinal permeability. It is widely used in integrative medicine for food sensitivity management.

Saccharomyces boulardii is a non-pathogenic probiotic yeast with established evidence for improving gut barrier function and GI microbiota health, and is used clinically in conditions of intestinal inflammation and dysbiosis that underlie food sensitivity. The European Society of Paediatric Gastroenterology recommends it for GI conditions and it has documented effects on reducing intestinal permeability.

Sucrase deficiency represents a specific, enzyme-based food sensitivity to sucrose and sucrose-containing foods. Patients with CSID or partial sucrase-isomaltase deficiency exhibit adverse GI reactions to sucrose consumption that are reproducible and dose-dependent. The condition can be misidentified as a food allergy, but it is a carbohydrate maldigestion disorder confirmed by breath testing or enzyme assay.

Pancreatic enzyme insufficiency is associated in the clinical and naturopathic literature with incomplete protein digestion, which may theoretically contribute to increased food antigenicity. In naturopathic and functional medicine traditions, pancreatic enzyme supplementation (including bovine pancreatin) has long been used to address food sensitivities and intolerances by improving macronutrient digestion. There is no direct human clinical trial evidence for bovine pancreas supplements specifically improving immunologically-defined food sensitivity.

Cellulase has a documented traditional role in reducing food sensitivities related to plant fiber consumption, based on the reasoning that incomplete cellulose digestion contributes to immune reactivity and GI hypersensitivity to certain fibrous plant foods. A 2024 ileostomy RCT noted that digestive enzyme supplementation including cellulase may 'decrease food sensitivities' by accelerating breakdown of complex food matrices. No direct human RCT has tested cellulase specifically against food sensitivity endpoints.